A New Kind of MS Drug for Progressive MS: What to Know About BTK Inhibitors
BTK inhibitors are a new approach for progressive MS. Roche’s fenebrutinib hit its Phase 3 goal while Sanofi’s tolebrutinib got an FDA CRL. Here is the honest picture.
Generic Copaxone Is Here: What the First Glatiramer Acetate Generic Means for MS Costs
The FDA approved the first complex generic of Copaxone (glatiramer acetate) for relapsing MS in January 2026. Here is what it means for cost, insurance, and access.